Story
Abcellera Stock Surges Over 30% on Positive Phase 2 Menopause Drug Data

Abcellera Biologics (NASDAQ: ABCL) stock surged 30.3% in pre-open trading after the company reported that its drug candidate, ABCL635, met the primary efficacy endpoint in a Phase 2 clinical trial. The trial evaluated the antibody for treating moderate-to-severe vasomotor symptoms, commonly known as hot flashes, associated with menopause.
Trial Results Detail Clinical Success
The randomized, double-blind, placebo-controlled study enrolled 92 postmenopausal women. According to the company, the trial demonstrated a 83% mean reduction in hot flash frequency at week four for patients receiving ABCL635. The treatment group experienced a reduction of 8.8 events per day, compared to a 3.5 event-per-day reduction for the placebo group.
ABCL635 is a potential first-in-class, non-hormonal antibody that targets the neurokinin 3 receptor (NK3R). This positive readout marks the first Phase 2 data from AbCellera’s GPCR and ion channel platform, a significant milestone for its internal drug development pipeline that investors have been closely monitoring.
AdMarket Reaction and Context
The sharp upward move in Abcellera's stock was entirely company-specific, standing in contrast to the broader market, which saw the S&P 500, Dow Jones, and Nasdaq all trading modestly lower in the pre-market session. The positive clinical news propelled the stock above its previous 52-week high, resetting investor expectations for the drug's commercial potential.
The announcement follows recent positive sentiment from Wall Street analysts. In the days leading up to the data release, Cantor Fitzgerald raised its price target on the stock to $12, Stifel lifted its target to $9, and Piper Sandler reiterated a Buy rating. The company's strong financial position, including $567 million in cash and over $675 million in total available liquidity, further supports its ability to fund its ongoing pipeline development.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.